After a phase 3 push the livmoniplimab plan falters.
ApexOnco Front Page
Recent articles
The company discontinues one of its two KRAS G12D degraders.
Meanwhile, Zai Lab faces delays in its pivotal DLL3 trial.
And AbbVie and Genmab scoop their ASH presentation with new data.
The company adds royalty aggregation to its R&D business.
But Enhertu is coming.
The restructured biotech’s new lead project enters phase 1.
A new first-line maintenance phase 3 joins a relapsed pivotal phase 2 study.
